TaiMed Biologics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, TaiMed Biologics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

TaiMed Biologics: 9 sponsored US clinical trials, 1 recruiting.

TaiMed Biologics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV-1-infection, with 1 trials.

Top-decile sponsor footprint

TaiMed Biologics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the TaiMed Biologics pipeline

1 recruiting of 9 indexed (11% open); 7 completed (78%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: HIV-1-infection (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TaiMed Biologics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share TaiMed Biologics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot).

TaiMed Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this TaiMed Biologics page

9 registered trials is a research-attention snapshot, not an endorsement of TaiMed Biologics or any single study.

  • 1 of TaiMed Biologics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV-1-infection is the condition TaiMed Biologics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV-1-infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. TaiMed Biologics pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.